Abstract
Purpose: We sought to evaluate the prognostic/predictive value of ERCC1 and XPF in patients with nonmetastatic nasopharyngeal carcinoma (NPC) treated with curative intent. Methods and Materials: ERCC1 and XPF protein expression was evaluated by immunofluorescence combined with automated quantitative analysis (AQUA) using the FL297 and 3F2 antibodies, respectively. ERCC1 and XPF protein expression levels were correlated with clinical outcomes. Results: Patient characteristics were as follows: mean age 52 years (range, 18-85 years), 67% male, 72% Karnofsky performance status (KPS) ≥90%, World Health Organization (WHO) type 1/2/3 = 12%/28%/60%, stage III/IV 65%. With a median follow-up time of 50 months (range, 2.9 to 120 months), the 5-year overall survival (OS) was 70.8%. Median standardized nuclear AQUA scores were used as cutpoints for ERCC1 (n=138) and XPF (n=130) protein expression. Agreement between dichotomized ERCC1 and XPF scores was high at 79.4% (kappa = 0.587, P<.001). Neither biomarker predicted locoregional recurrence, DFS, or OS after adjustment for age and KPS, irrespective of stratification by stage, WHO type, or treatment. Conclusions: Neither ERCC1 nor XPF, analyzed by quantitative immunohistochemistry using the FL297 and 3F2 antibodies, was prognostic or predictive in this cohort of NPC patients.
Jagdis, Amanda;
[1]
Phan, Tien;
[2]
Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)];
Klimowicz, Alexander C.;
[3]
Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)];
Laskin, Janessa J.;
[4]
Faculty of Medicine, University of British Columbia, Vancouver, British Columbia (Canada)];
Lau, Harold Y.;
[2]
Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)];
Petrillo, Stephanie K.;
[5]
Siever, Jodi E.;
[6]
Thomson, Thomas A.;
[7]
Faculty of Medicine, University of British Columbia, Vancouver, British Columbia (Canada)];
Magliocco, Anthony M.;
[8]
Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)];
Hao, Desirée;
[9]
Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)]
- Department of Internal Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia (Canada)
- Department of Radiation Oncology, Tom Baker Cancer Centre, Calgary, Alberta (Canada)
- Department of Oncology, Tom Baker Cancer Centre, Calgary, Alberta (Canada)
- Department of Medical Oncology, British Columbia Cancer Agency–Vancouver, Vancouver, British Columbia (Canada)
- Functional Tissue Imaging Unit, Translational Research Laboratory, Tom Baker Cancer Centre, Calgary, Alberta (Canada)
- Department of Biostatistics, Public Health Innovation and Decision Support Population and Public Health, Alberta Health Services, Calgary, Alberta (Canada)
- Department of Pathology, British Columbia Cancer Agency–Vancouver, Vancouver, British Columbia (Canada)
- Department of Pathology, Tom Baker Cancer Centre, Calgary, Alberta (Canada)
- Department of Medical Oncology, Tom Baker Cancer Centre, Calgary, Alberta (Canada)
Citation Formats
Jagdis, Amanda, Phan, Tien, Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)], Klimowicz, Alexander C., Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)], Laskin, Janessa J., Faculty of Medicine, University of British Columbia, Vancouver, British Columbia (Canada)], Lau, Harold Y., Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)], Petrillo, Stephanie K., Siever, Jodi E., Thomson, Thomas A., Faculty of Medicine, University of British Columbia, Vancouver, British Columbia (Canada)], Magliocco, Anthony M., Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)], Hao, Desirée, and Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)].
Assessment of ERCC1 and XPF Protein Expression Using Quantitative Immunohistochemistry in Nasopharyngeal Carcinoma Patients Undergoing Curative Intent Treatment.
United States: N. p.,
2013.
Web.
doi:10.1016/J.IJROBP.2012.09.032.
Jagdis, Amanda, Phan, Tien, Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)], Klimowicz, Alexander C., Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)], Laskin, Janessa J., Faculty of Medicine, University of British Columbia, Vancouver, British Columbia (Canada)], Lau, Harold Y., Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)], Petrillo, Stephanie K., Siever, Jodi E., Thomson, Thomas A., Faculty of Medicine, University of British Columbia, Vancouver, British Columbia (Canada)], Magliocco, Anthony M., Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)], Hao, Desirée, & Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)].
Assessment of ERCC1 and XPF Protein Expression Using Quantitative Immunohistochemistry in Nasopharyngeal Carcinoma Patients Undergoing Curative Intent Treatment.
United States.
https://doi.org/10.1016/J.IJROBP.2012.09.032
Jagdis, Amanda, Phan, Tien, Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)], Klimowicz, Alexander C., Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)], Laskin, Janessa J., Faculty of Medicine, University of British Columbia, Vancouver, British Columbia (Canada)], Lau, Harold Y., Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)], Petrillo, Stephanie K., Siever, Jodi E., Thomson, Thomas A., Faculty of Medicine, University of British Columbia, Vancouver, British Columbia (Canada)], Magliocco, Anthony M., Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)], Hao, Desirée, and Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)].
2013.
"Assessment of ERCC1 and XPF Protein Expression Using Quantitative Immunohistochemistry in Nasopharyngeal Carcinoma Patients Undergoing Curative Intent Treatment."
United States.
https://doi.org/10.1016/J.IJROBP.2012.09.032.
@misc{etde_22224427,
title = {Assessment of ERCC1 and XPF Protein Expression Using Quantitative Immunohistochemistry in Nasopharyngeal Carcinoma Patients Undergoing Curative Intent Treatment}
author = {Jagdis, Amanda, Phan, Tien, Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)], Klimowicz, Alexander C., Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)], Laskin, Janessa J., Faculty of Medicine, University of British Columbia, Vancouver, British Columbia (Canada)], Lau, Harold Y., Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)], Petrillo, Stephanie K., Siever, Jodi E., Thomson, Thomas A., Faculty of Medicine, University of British Columbia, Vancouver, British Columbia (Canada)], Magliocco, Anthony M., Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)], Hao, Desirée, and Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)]}
abstractNote = {Purpose: We sought to evaluate the prognostic/predictive value of ERCC1 and XPF in patients with nonmetastatic nasopharyngeal carcinoma (NPC) treated with curative intent. Methods and Materials: ERCC1 and XPF protein expression was evaluated by immunofluorescence combined with automated quantitative analysis (AQUA) using the FL297 and 3F2 antibodies, respectively. ERCC1 and XPF protein expression levels were correlated with clinical outcomes. Results: Patient characteristics were as follows: mean age 52 years (range, 18-85 years), 67% male, 72% Karnofsky performance status (KPS) ≥90%, World Health Organization (WHO) type 1/2/3 = 12%/28%/60%, stage III/IV 65%. With a median follow-up time of 50 months (range, 2.9 to 120 months), the 5-year overall survival (OS) was 70.8%. Median standardized nuclear AQUA scores were used as cutpoints for ERCC1 (n=138) and XPF (n=130) protein expression. Agreement between dichotomized ERCC1 and XPF scores was high at 79.4% (kappa = 0.587, P<.001). Neither biomarker predicted locoregional recurrence, DFS, or OS after adjustment for age and KPS, irrespective of stratification by stage, WHO type, or treatment. Conclusions: Neither ERCC1 nor XPF, analyzed by quantitative immunohistochemistry using the FL297 and 3F2 antibodies, was prognostic or predictive in this cohort of NPC patients.}
doi = {10.1016/J.IJROBP.2012.09.032}
journal = []
issue = {5}
volume = {85}
journal type = {AC}
place = {United States}
year = {2013}
month = {Apr}
}
title = {Assessment of ERCC1 and XPF Protein Expression Using Quantitative Immunohistochemistry in Nasopharyngeal Carcinoma Patients Undergoing Curative Intent Treatment}
author = {Jagdis, Amanda, Phan, Tien, Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)], Klimowicz, Alexander C., Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)], Laskin, Janessa J., Faculty of Medicine, University of British Columbia, Vancouver, British Columbia (Canada)], Lau, Harold Y., Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)], Petrillo, Stephanie K., Siever, Jodi E., Thomson, Thomas A., Faculty of Medicine, University of British Columbia, Vancouver, British Columbia (Canada)], Magliocco, Anthony M., Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)], Hao, Desirée, and Faculty of Medicine, University of Calgary, Calgary, Alberta (Canada)]}
abstractNote = {Purpose: We sought to evaluate the prognostic/predictive value of ERCC1 and XPF in patients with nonmetastatic nasopharyngeal carcinoma (NPC) treated with curative intent. Methods and Materials: ERCC1 and XPF protein expression was evaluated by immunofluorescence combined with automated quantitative analysis (AQUA) using the FL297 and 3F2 antibodies, respectively. ERCC1 and XPF protein expression levels were correlated with clinical outcomes. Results: Patient characteristics were as follows: mean age 52 years (range, 18-85 years), 67% male, 72% Karnofsky performance status (KPS) ≥90%, World Health Organization (WHO) type 1/2/3 = 12%/28%/60%, stage III/IV 65%. With a median follow-up time of 50 months (range, 2.9 to 120 months), the 5-year overall survival (OS) was 70.8%. Median standardized nuclear AQUA scores were used as cutpoints for ERCC1 (n=138) and XPF (n=130) protein expression. Agreement between dichotomized ERCC1 and XPF scores was high at 79.4% (kappa = 0.587, P<.001). Neither biomarker predicted locoregional recurrence, DFS, or OS after adjustment for age and KPS, irrespective of stratification by stage, WHO type, or treatment. Conclusions: Neither ERCC1 nor XPF, analyzed by quantitative immunohistochemistry using the FL297 and 3F2 antibodies, was prognostic or predictive in this cohort of NPC patients.}
doi = {10.1016/J.IJROBP.2012.09.032}
journal = []
issue = {5}
volume = {85}
journal type = {AC}
place = {United States}
year = {2013}
month = {Apr}
}